Skip to main content

Table 1 Association between 25-hydroxyvitamin D and hip osteoarthritis: data from three studies of community-based populations

From: Association between circulating 25-hydroxyvitamin D concentrations and hip replacement for osteoarthritis: a prospective cohort study

Author, Year, Country

Follow-up

Participants

Outcome measurement

Number of cases

Adjustment

Main findings 25(OH)D nmol/l; OR/RR/HR; 95% CI

Konstari, 2012, Finland [10]

22-23 years

805 Finnish adults from the Mini-Finland Health Examination Survey

Age: ≥30 years

55.3% women

Hip OA was defined by

-documented history of previously diagnosed hip OA

-hip arthroplasty due to OA

17 men and 23 women

age, gender, education, BMI, physical workload, smoking, leisure time physical activity, injuries, and season of blood draw

Q1 (13-33): reference

Q2 (34-43): 1.22; 0.46-3.21

Q3 (44-56): 1.15; 0.43-3.04

Q4 (57-180): 0.72; 0.24-2.13

P for trend: 0.23

Konstari, 2014, Finland [9]

10 years

5274 adults living in mainland Finland from the Health 2000 Survey

Age ≥ 30 years

54.1% women

Incidence of hip OA was drawn from the National Health Care Register using International Classification of Diseases, 10th revision (ICD-10)

45 participants

Age, gender, BMI, current physical workload, education, smoking, leisure time physical activity, time of serum collection, injuries and difficulty in walking due to discomfort or trouble in the knee or hip

Q1 (0-33): reference

Q2 (34-42): 2.23; 0.76-6.55

Q3 (43-54): 2.96; 1.07-8.21

Q4 (55-134): 2.81; 1.01-7.85

P for trend 0.053

Hussain, 2015, Australia [8]

9.1 ± 2.7 years

9135 participants from the Australian Diabetes, Obesity and Lifestyle Study including population representative of Australia

Age: ≥40 years

54.3% women

Incidence of hip replacement for OA by linking cohort records to the Australian Orthopaedic Association National Joint Replacement Registry

90 men and 111 women

Age, BMI, ethnicity, smoking status, physical activity, season of blood collection, latitude, hypertension, diabetes, and Area-level disadvantage.

Men

Q1 (≤51): reference

Q2 (52-65): 2.02; 1.01-4.06

Q3 (66-81): 2.17; 1.08-4.06

Q4 (≥82): 2.30; 1.09-4.82

P for trend 0.04

Women

Q1 (≤41): reference

Q2 (42-54): 1.21; 0.70-2.09

Q3 (55-69): 1.08; 0.61-1.91

Q4 (≥70): 1.29; 0.71-2.34

P for trend 0.49

  1. OA osteoarthritis, 25(OH)D 25-hydroxyvitamin D, Q quartile, OR odds ratio, RR relative risk, HR hazard ratio, CI confidence interval